SelectBIO Virtual Conference


Latest Advances 2021


JANUARY 12, 2021


Join us on January 12, 2021 for our virtual conference in partnership with SelectBIO. This timely web conference run in a virtual format brings together researchers from academia and industry from around the world to engage and present the latest data in the broader field of cell culture. With the increasing emphasis upon 3D-Cell Culture, Organoid and Spheroid research plus the convergence of microfluidics and cell culture in the form of Organ-on-a-Chip Devices, there is increasing need for real-time monitoring and sensing of the cell culture milieu.

Scientific Bioprocessing, Inc. is the Exclusive Corporate Sponsor of this Web Conference.


Register for free – we welcome researchers from academic and industry from around the world to participate. 



Agenda Topics

  • 3D Culture to Organoid to Organ-on-a-Chip Continuum
  • 3D-Organoid Models for Disease
  • Cell Therapies Manufacturing
  • Latest Sensing Technologies
  • Microfluidics for the Development of Organ-on-a-Chip Devices
  • Organoids-on-a-Chip
  • Tumor Organoids and Spheroid
Keynote speakers

Doris A. Taylor

Innovator and Entrepreneur, RegenMedix Technologies & RegenMedix Consulting, LL.C, Ph.D., Hon D.Sc., FAHA, FACC, FESC, Sr Member NAI

Dr. Taylor is a dynamic innovator, scientist and entrepreneur and a global thought leader in regenerative medicine. She has published over 180 papers, holds over 30 patents, and is the founder of multiple companies. She has trained hundreds of undergraduate, graduate, and post-graduate fellows worldwide in her laboratories in the U.S. and Europe. Although she has held academic positions for over 20 years, she recently founded RegenMedix Consulting LLC to enable academic and commercial enterprises in the regenerative medicine space.

Ohad Karnieli

Founder & CEO, ADVA Biotechnology

A well-known international expert in cell therapy with extensive knowledge of the industry. Dr Karnieli is the founder and President of Atvio Biotech, a leading Innovation center for cell and gene therapy. Former VP of Technology & Manufacturing at Pluristem Therapeutics, and the former VP medical device at Goji solutions. Dr Karnieli served as the chair of several industry committees such as the process & product development committee of the International Society for Cellular Therapies, expert member in the ISO TC276 Biotechnology standard committee and the former chair of the science and technology committee of the Alliance for Regenerative Medicine. Furthermore, Dr Karnieli serves as an advisor and board member to several of the lead cell therapy developing companies. Dr Karnieli earned his PhD on Cell and Gene Therapy in the Sackler School of Medicine of the Tel Aviv University. Furthermore, he holds an MBA from the Haifa University business management school.


Govind Rao

Director, Center for Advanced Sensor Technology and Professor, Chemical, Biochemical and Environmental Engineering, UMBC, Baltimore

Govind Rao is Professor of Chemical & Biochemical Engineering and Director of the Center for Advanced Sensor Technology at the University of Maryland, Baltimore County. He obtained his Bachelor of Science degree in Chemical Engineering from the Indian Institute of Technology, Madras. His Ph.D. degree was from Drexel University in Chemical Engineering. He has been a faculty member at UMBC since 1987.

Dr. Rao’s research has focused on applications of fluorescence spectroscopy to bioprocess engineering. His lab has developed next-generation sensors for low-cost non-invasive monitoring of oxygen, pH and pCO2 in bioreactors. In addition, novel sensors for glucose and glutamine have been developed. These sensors have led to a paradigm shift in bioprocess technology, as they collectively enable High Throughput Bioprocessing. In addition, the Rao lab has focused on developing novel applications of Green Fluorescent Protein in Bioprocessing. Its unique fluorescent properties and ease of use in a variety of culture systems have provided new insights into heterologous protein production. Recently, the Rao lab has started developing the next generation of sensors based on surface plasmon coupled fluorescence. These promise to lead to ultra-sensitive and ultra-fast sensors but at low-cost.

He has received several awards. These include the Presidential Young Investigator Award from the National Science Foundation, Outstanding Teaching and Research Awards from UMBC, the Van Lanen Award from the American Chemical Society, the Gaden Award from Biotechnology & Bioengineering, the University System of Maryland Regents Award for Excellence in Research and he has been named a 2003 Innovator of the Year by the Maryland Daily Record. Dr. Rao has several patents and these have been licensed to Fluorometrix, which he co-founded. Dr. Rao has served as the Chair of the Biotechnology Division of the American Chemical Society and on the Editorial Board of several prominent journals. In 2007, he was elected as a Fellow of the American Association for the Advancement of Science.


Jake Boy

Senior Application Scientist

Jake earned his BA in Organismic and Evolutionary Biology at Harvard University. He has a professional background in research labs, genetics, and cell culturing. As an applications scientist at Scientific Bioprocessing, Jake supports new product development and testing and problem solves for each customer’s unique bio-application. Jake is dedicated to improving the science surrounding cell culture and helping customers attain their scientific goals.


Alicia Henn

Chief Scientific Officer

Alicia Henn is Chief Scientific Officer of BioSpherix, Ltd. She holds a PhD in Molecular Pharmacology and Cancer Therapeutics from Roswell Park Cancer Institute (2000). She also holds an MBA (2013) from University of Rochester, where she was a B cell biologist at the Center for Biodefense Immune Modeling. She is an inventor with patents from her work at RPCI, University of Rochester, and BioSpherix. Alicia writes the company blog, Cytocentric, and is also the founder/owner of the In Vitro Reproducibility Group on LinkedIn. Her research program focuses on physiologically relevant in vitro cell environments for reducing the time, money, and animals used to get novel therapeutics to the humans that need them.

Sudhin Biopharma Co.

Dhinakar Kompala

Chairman & CEO

Dhinakar Kompala obtained his B. Tech. in Chemical Engineering from Indian Institute of Technology, Madras, India in 1979 and his M.S. and Ph.D. in Chemical Engineering from Purdue University, USA in 1982 and 1984 respectively. He served on the faculty of the Department of Chemical and Biological Engineering at the University of Colorado, Boulder since 1985. He was a recipient of Presidential Young Investigator award from National Science Foundation in 1988.

Dhinakar’s research expertise is in bioprocess engineering, recombinant mammalian and microbial cell cultures, bioreactor design and operating strategies, metabolic engineering, and modeling of biological growth and production processes. He trained over 30 graduate and postdoctoral researchers, most of whom have joined the biotechnology industry. He served on editorial boards of the Journal of Biotechnology, International Journal of Biological Sciences and as Section Editor of BMC Biotechnology.

Dhinakar was co-founder of a biotech startup company, Richcore Lifesciences Private Limited, in Bangalore, India in July 2008. He served as the Chief Scientific Officer, Director of R&D, and on the Board of Directors of this growing company until November 2012. Taking a phased early retirement from the University of Colorado in May 2014, Dhinakar is now devoting full time to his new biotech startup, Sudhin Biopharma Company in Superior, CO and its subsidiary R&D operations at Sudhin Biotech Private Limited in Chennai, India.

O2M Technologies, LLC

Mrignayani Kotecha

Chief Executive Officer

Dr. Mrignayani Kotecha is a founding member and the CEO of O2M Technologies, LLC. O2M was formed with the purpose of bringing pulse electron paramagnetic resonance oxygen imaging (EPROI) to the market. Our commitment is to use oxygen imaging to build better cancer, type I diabetes, and tissue engineering regenerative medicine therapies. O2M has developed a 25 mT preclinical oxygen imager, JIVA-25, that has a small footprint and can be installed in any laboratory within a small space and regular outlet. O2M also established an “Oxygen Measurement Core” service facility that performs in vitro and in vivo service projects in diabetes and cancer in collaboration with industry and academic partners. Prior to starting O2M, Dr. Kotecha was a research faculty in the Bioengineering department at the University of Illinois at Chicago, a staff scientist at the University of Duisburg-Essen (Germany) and the Weizmann Institute of Science (Israel), and an assistant professor of Physics at the Government Model Science College, Jabalpur, India. She holds a Ph.D. in Physics from Jabalpur University, India. Dr. Kotecha is the lead editor of the book “Magnetic Resonance Imaging in Tissue Engineering” (Wiley, 2017) and the task group chair for the ASTM standard F3224-17 “Standard Test Method for Evaluating Growth of Engineered Cartilage Tissue using Magnetic Resonance Imaging”.


John Moore


John is President of Scientific Bioprocessing and Chairman of the Board of our parent, Scientific Industries (SCND-OTCQX). He is a magnificent amateur — sometimes the emphasis on amateur and sometimes magnificent. His 2002 acquisition of interests in sixteen drug delivery businesses from Elan Pharmaceuticals really sparked his interest in life sciences.

Wake Forest Institute for Regenerative Medicine

Shiny Rajan

Research Associate

Dr. Shiny Rajan, PhD., MBA is currently a postdoctoral research associate at Wake Forest Institute for Regenerative Medicine (WFIRM), North Carolina, USA. She received her PhD in Biomedical Engineering and MBA dual-degrees in 2019 at Virginia Tech-Wake Forest University. Her academic work focused on developing patient-specific cancer models that serves as a platform to develop chemotherapy strategies and micro-organ architecture like “Body-on-a-chip” or “organ-on-a-chip” technologies for drug discovery and toxicity testing. She joined WFIRM, as a Research Scientist and is leading the project to develop a 3D printed “lung-on-a-chip” platform to understand organ toxicity caused by drugs and bioweapons and develop treatment strategies for organ regeneration. She has delivered over 30 scientific presentations, authored several publications and book chapters, and volunteers in multiple community outreach program that aims to inspire young minds to pursue career in STEM field. She is a recipient of ‘Winston Under 40 Leadership Award’ by the Greater Winston-Salem, Inc in 2020 and ‘Innovation Excellence Award’ by the NIH Nanotechnology Startup Challenge in Cancer in 2016 along with several awards for her scientific presentation in international conferences.

Promega Corporation

Terry Riss

Global Strategic Marketing Manager Cell Health

Dr. Riss received a PhD in Cell Biology from the University of Illinois in 1978 in the field of mammary gland biology. He did postdoctoral work at the University of Texas Medical School developing bioassays to study breast cancer. Dr. Riss moved to the Biotechnology division of Schering Plough in 1988 to develop interleukin/cytokine bioassays to support IND filings. Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 where he has held several R&D and Project Management positions. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and lead efforts to promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Global Strategic Manager, Cell Health involved in outreach educational training activities. Dr. Riss serves as a co-editor of the NIH Assay Guidance Manual.


Thomas Shupe

Assistant Professor

I began my career in cancer research where I identified several alternative pathways for carcinogen metabolism that are activated during liver regeneration and was a key player in the characterization of several molecular factors that govern the phenotypes of both liver stem cells and liver tumor cells. I have more than 20 years’ experience working with in vivo and in vitro models for human disease. More recently, I transitioned to the field of regenerative medicine and was the first to publish a method for the decellularization of intact liver. These decellularized matrices are currently under evaluation as scaffolds for clinical scale liver bioengineering. Together with colleagues at the Institute, we have developed methods for incorporating decellularized tissue matrices into cell culture substrates that provide exceptional support for human primary cells. I serve as the scientific coordinator for the ECHO “Body-on-a-Chip” program and as the primary investigator for a universal media project.

University of oxford

Pawel Swietach

Professor of Physiology

Research in my lab is driven by an interest in how biological processes are affected by chemical acidity. All tissues are exquisitely sensitive to changes in acidity (often expressed on a pH scale), therefore the remit of our research is broad. However, our two main pillars relate to the heart and to cancer. Acidity has a powerful effect on cardiac biology and is particularly important in cardiac diseases. In tumors, acidity is a chemical signature that influences disease progression. By discovering the mechanisms of these pH-responses, we hope to deliver new insights that may lead to better diagnosis, management and treatment of cardiovascular diseases and cancer. Most of our work is supported by the European Research Council (ERC) and the British Heart Foundation (BHF).

University of Calgary

Derek Toms

PostDoctoral Fellow

Dr. Derek Toms is an interdisciplinary scientist with expertise in cellular and molecular biology, tissue engineering and bioinformatics. He is presently a postdoctoral researcher at the University of Calgary in the Department of Comparative Biology and Experimental Medicine, where he focuses on developing scalable cell-based therapies for the treatment of diabetes. His investigation of oxygen diffusion in 3D cell culture has supported commercial bioreactor development that is necessary for generating large numbers of uniform cellular aggregates to scale up translational research.


Dr. Toms continually looks for unique ways to develop and incorporate computer sciences in biological research; he is presently integrating mathematically-modeled experimental design with liquid handling robotics to mass-produce complex tissues from stem cells. By developing these innovative tools, Dr. Toms aims to improve our ability to analyze complex biological systems using a process engineering approach that models and simulates natural phenomena to ultimately provide novel insight to understand biological trends for the benefit of society.

Watch now


Registered Customers

If you have an account with us please log in.

Your Cart

Sub Total $0